AstraZeneca signed a Memorandum of Understanding with Wuxi High-tech District to become a Founding Partner of a new life sciences park located in Wuxi, China. The new park will provide startup companies with shared resources, including laboratories, equipment and services. In addition, AstraZeneca will offer its global R&D network to support end-to-end development and commercialization of medicines. AstraZeneca said the International Life Science Innovation Park will bring together local and international companies, government and medical/academic institutions.
Source: China Biotoday
